Natalia Kunst, PhD

Natalia Kunst, PhD is a decision sciences and health economics researcher who focuses on applying decision-analytic and statistical methods in cancer, genetics and precision medicine to assess and identify efficient strategies that would improve patients’ health outcomes, and to design and prioritize clinical research in limited-resource settings, also focusing on health disparities. She is currently engaged in health policy-making and research in Norway through two positions. First, Natalia is a Senior Advisor at the Norwegian Directorate of Health. This position has afforded her the opportunity to gain experience in national policy-making by performing health economic analyses of preventive interventions, priority settings in health, development of national guidelines, and by serving as a Norwegian delegate in international organizations such as OECD. Additionally, part of her time is dedicated to teaching and research as an Associate Professor in the Department of Health Management and Health Economics at the University of Oslo, Norway.

Dr. Kunst is also a Research Affiliate at the Yale University School of Public Health and an Affiliated Member at the Center for Healthcare Research in Pediatrics (CHeRP), Harvard Medical School and Harvard Pilgrim Health Care Institute. She co-founded and has co-led the Collaborative Network for Value of Information (ConVOI), which is an international group of over 20 researchers with interests in the application and development of methods for value of information calculation. She completed her PhD in Health Economics and Health Policy with concentration in Health Decision Science at the University of Oslo, Norway, and was a Postgraduate Research Fellow at Yale University School of Medicine and a Visitng PhD Candidate at Yale School of Public Health. Prior to her PhD, she worked as a Senior Health Economist in Norway, developing and adapting decision-analytic models and preparing Health Technology Assessment (HTA) applications predominantly in cancer in collaboration with the Norwegian Medicines Agency.